newsfilter
← Latest News
GlobeNewswire·

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

LXRX
  • Lexicon Pharmaceuticals reported $0.7 million in total revenue for Q2 2026, down from $28.9 million in Q2 2025, resulting in a net loss of $31.8 million.
  • Enrollment is complete in the Phase 3 SONATA-HCM study for sotagliflozin, with top-line data expected in Q1 2027.
  • NDA resubmission activities for ZYNQUISTA in type 1 diabetes are nearing completion, with a resubmission anticipated in Q4 2026.
  • Phase 1 clinical development of LX9851 for obesity is ongoing with Novo Nordisk, targeting completion in Q1 2027.
  • Viatris holds the license for sotagliflozin outside the U.S. & Europe, having secured approvals in the UAE & Bahrain and submitting applications in several other markets.
  • Lexicon holds a $100 million loan facility with Hercules Capital, with $55 million already funded to repay previous debt.
  • Cash, investments, and restricted cash increased to $190.6 million as of June 30, 2026, driven by $96.2 million in proceeds from a stock sale in February 2026.
  • Research and development expenses rose to $17.4 million in Q2 2026 due to higher costs related to the SONATA-HCM trial.
  • Pilavapadin (LX9211), an investigational AAK1 inhibitor for neuropathic pain, continues to be evaluated for strategic opportunities.